Bilateral same day intravitreal anti-VEGF treament: Is it safe?

Session Details

Session Title: Free Paper Session 9: AMD III

Session Date/Time: Friday 08/09/2017 | 08:00-09:30

Paper Time: 08:18

Venue: Room 117

First Author: : R.Cahill UK

Co Author(s): :    D. Sahu   C. Knight   I. Careba   D. Malik                    

Abstract Details

Purpose:

To report the outcomes of same-day, bilateral intravitreal anti-vascular endothelial growth factor (VEGF) therapy following a retrospective review of patients treated within a large United Kingdom Teaching Hospital.

Setting:

Tertiary NHS UK Eye Service

Methods:

A retrospective audit of complication rates of 7390 eyes of 635 patients treated with same day bilateral Anti-VEGF injections of Aflibercept, Bevacizumab or ranibizumab between January 5, 2012 and September 20, 2016 for Wet Age Related Macular Degeneration, Retinal Vein occlusion and Diabetic Macular Oedema. These treatments were administered by Orthoptists, Nurses and Medical Staff.

Results:

The incidence of adverse effects was low and same day treatment is generally well tolerated. No cases of bilateral endophthalmitis were reported and complication rates were comparable to report literature.

Conclusions:

This study provides a robust evidence base to suggest that bilateral same day intravitreal treatment is general well tolerated and complication rates are comparable to unilateral treatment.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy